Advances in Nanomedicine for the Treatment of Alzheimer’s and Parkinson’s Diseases
- 14 April 2016
- journal article
- review article
- Published by Taylor & Francis in Nanomedicine
- Vol. 11 (10) , 1267-1285
Abstract
Alzheimer‘s disease and Parkinson’s disease are the most common neurodegenerative diseases worldwide. Despite all the efforts made by the scientific community, current available treatments have limited effectiveness, without halting the progression of the disease. That is why, new molecules such as growth factors, antioxidants and metal chelators have been raised as new therapeutical approaches. However, these molecules have difficulties to cross the blood–brain barrier limiting its therapeutic effect. The development of nanometric drug delivery systems may permit a targeted and sustained release of old and new treatments offering a novel strategy to treat these neurodegenerative disorders. This review summarized the main investigated drug delivery systems as promising approaches to treat Alzheimer‘s disease and Parkinson’s disease.Keywords
Funding Information
- Ministerio de Economía y Competitividad (SAF2013–42347-R)
- the University of the Basque Country (UPV/EHU; UFI 11/32)
- Basque Government (Saiotek S-PE13UN048, GIC IT 794/13)
- FEDER funds
This publication has 101 references indexed in Scilit:
- Growth factors in synaptic functionFrontiers in Synaptic Neuroscience, 2013
- Potential therapeutic effect of nanobased formulation of rivastigmine on rat model of Alzheimer's diseaseInternational Journal of Nanomedicine, 2013
- Serum Brain-Derived Neurotrophic Factor Levels in Different Neurological DiseasesBioMed Research International, 2013
- Novel surface modified solid lipid nanoparticles as intranasal carriers for ropinirole hydrochloride: application of factorial design approachDrug Delivery, 2012
- Controlled-release levodopa methyl ester/benserazide-loaded nanoparticles ameliorate levodopa-induced dyskinesia in ratsInternational Journal of Nanomedicine, 2012
- Biodegradable Microspheres Loaded with an Anti-Parkinson Prodrug: An in Vivo Pharmacokinetic StudyMolecular Pharmaceutics, 2011
- Sustained-release formulation of levodopa methyl ester/benserazide for prolonged suppressing dyskinesia expression in 6-OHDA-leisoned ratsNeuroscience Letters, 2011
- Treatment of Parkinson's disease: nanostructured sol–gel silica–dopamine reservoirs for controlled drug release in the central nervous systemInternational Journal of Nanomedicine, 2010
- Nanoparticle–chelator conjugates as inhibitors of amyloid-β aggregation and neurotoxicity: A novel therapeutic approach for Alzheimer diseaseNeuroscience Letters, 2009
- Functional Effects of AAV2-GDNF on the Dopaminergic Nigrostriatal Pathway in Parkinsonian Rhesus MonkeysHuman Gene Therapy, 2009